Exelixis Inc. | Mutual Funds
Mutual Funds that own Exelixis Inc.
Fidelity Growth Company Fund
11,394,311
3.82%
-683,588
0.44%
07/31/2018
iShares Core S&P Mid Cap ETF
7,706,181
2.59%
6,224
0.28%
09/06/2018
Vanguard Small Cap Index Fund
7,469,377
2.5%
96,110
0.14%
07/31/2018
Vanguard Total Stock Market Index Fund
7,466,804
2.5%
6,900
0.02%
07/31/2018
Vanguard Small Cap Growth Index Fund
4,264,522
1.43%
63,201
0.31%
07/31/2018
SPDR S&P Biotech ETF
3,780,543
1.27%
9,726
1.21%
09/06/2018
Vanguard Extended Market Index Fund
3,739,805
1.25%
41,363
0.1%
07/31/2018
First Trust NYSE Arca Biotechnology Index Fund
3,477,947
1.17%
0
2.82%
09/05/2018
iShares Nasdaq Biotechnology ETF
3,430,719
1.14%
-44,856
0.66%
09/06/2018
SPDR S&P Mid Cap 400 ETF Trust
3,222,099
1.08%
0
0.28%
09/05/2018
| Address |
1851 Harbor Bay
Parkway Alameda California 94502
United States
|
|
Employees
|
- |
| Website |
http://www.exelixis.com |
| Updated |
07/08/2019 |
| Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. |
